Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.45 |
| ▸ | CLK2 | P49760 | 2/20 | 0.45 |
| ▸ | CLK3 | P49761 | 2/20 | 0.45 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063306 | 0.87 | L3MBTL1 (0.51) | NAMPTS1PR1 | |
| SCHEMBL4062636 | 0.86 | NAMPT (0.52) | NAMPTS1PR1CXCR1CXCR2MAPK7 | |
| SCHEMBL15921626 | 0.81 | BUB1 (0.43) | NAMPTS1PR1CXCR1CXCR2DYRK1A | |
| SCHEMBL4064073 | 0.79 | S1PR1 (0.50) | S1PR1 | |
| SCHEMBL5072186 | 0.79 | NAMPT (0.53) | NAMPTS1PR1FLT3 | |
| SCHEMBL4060466 | 0.78 | SMN1; SMN2 (0.56) | NAMPTS1PR1 | |
| SCHEMBL4061677 | 0.77 | HTR2C (0.53) | POLBPIK3CAMTOR | |
| SCHEMBL17357221 | 0.76 | BUB1 (0.51) | NAMPTS1PR1DYRK1ACLK2CLK3 | |
| SCHEMBL4072949 | 0.76 | S1PR1 (0.49) | S1PR1MAPK7PIK3CAMTOR | |
| SCHEMBL13946964 | 0.76 | NAMPT (0.50) | NAMPTS1PR1CXCR1CXCR2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028945-B9 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2009-02-18 | — | — | EP | claimed |
| EP-1028945-B1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2007-07-11 | — | — | EP | claimed |
| US-20020035094-A1 | Substituted pyridine compounds and methods of use | AMGEN INC. | 2002-03-21 | — | — | US | claimed |
| US-6022884-A | PROPHYLAXIS OR TREATMENT OF INFLAMMATION | AMGEN INC. (US) | 2000-02-08 | — | — | US | claimed |
| EP-1028945-B9 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1028945-B1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-6458813-B1 | 2-CYCLOHEXYLOXY-5-(2-CHLOROPHENYLCARBONYLAMINO)PYRIDINE, FOR EXAMPLE; TREATING INFLAMMATION, PAIN, DIABETES, CANCER | AMGEN INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020035094-A1 | Substituted pyridine compounds and methods of use | AMGEN INC. | 2002-03-21 | — | — | US | disclosed |
| US-6333341-B1 | TUMOR NECROSIS FACTOR, ANTIINFLAMMATORY AGENTS AND ANALGESICS | AMGEN INC. | 2001-12-25 | — | — | US | disclosed |
| US-6184237-B1 | Substituted pyridine compounds and methods of use | AMGEN INC. | 2001-02-06 | — | — | US | disclosed |
| EP-1028945-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | Amgen Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| US-6022884-A | PROPHYLAXIS OR TREATMENT OF INFLAMMATION | AMGEN INC. (US) | 2000-02-08 | — | — | US | disclosed |
| WO-1999024404-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035094-A1 | Substituted pyridine compounds and methods of use | IL1B, IL6, IL1A | NAMPT 165/4885S1PR1 1142/4885CXCR1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.